Two new cyclic bisbibenzyl derivatives from Hebertus dicranus
Chang-Long Xu1, Jin-Xin Wang2, Hui-Liang Li2
1School of Pharmacy and Life Science, Jiujiang University, Jiujiang 332000, China.
Two novel cyclic bisbibenzyls from *Hebertus dicranus* were identified. Compound 2 showed moderate inhibitory activity against human cancer cell lines, suggesting potential for cancer therapy development.
Area of Science:
- Natural Product Chemistry
- Medicinal Chemistry
- Pharmacology
Background:
- *Hebertus dicranus* is a liverwort species.
- Cyclic bisbibenzyls are a class of natural products with potential biological activities.
Purpose of the Study:
- To isolate and characterize new compounds from *Hebertus dicranus*.
- To evaluate the in vitro anticancer activity of isolated compounds against human cancer cell lines.
Main Methods:
- Isolation and structure elucidation using 1D and 2D NMR spectroscopy.
- Determination of absolute configurations via circular dichroism (CD) spectroscopy.
- In vitro cytotoxicity assessment using the MTT assay.
Main Results:
- Two new cyclic bisbibenzyls (compounds 1 and 2) and isoplagiochins C (compound 3) were isolated.
- Compound 2 demonstrated moderate inhibitory activity against A549, HCT116, MDA-MB-231, and BEL7404 cancer cell lines, with IC50 values between 13.89 and 31.62 μmol·L(-1).
Conclusions:
- The study identified novel cyclic bisbibenzyls from *Hebertus dicranus*.
- Compound 2 shows potential as a lead compound for cancer therapy development.
- Further research into the modification and development of these compounds for cancer treatment is warranted.
Related Concept Videos
Diels–Alder Reaction Forming Bridged Bicyclic Products: Stereochemistry
Diels–Alder Reaction Forming Cyclic Products: Stereochemistry
Cycloaddition Reactions: Overview
[4+2] Cycloaddition of Conjugated Dienes: Diels–Alder Reaction
Intramolecular Claisen Condensation of Dicarboxylic Esters: Dieckmann Cyclization
Benzene to 1,4-Cyclohexadiene: Birch Reduction Mechanism


